{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:13:19Z","timestamp":1790100799077,"version":"4.0.1"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>There is growing scientific evidence for the therapeutic benefits of the Amazonian plant-based psychedelic \u201cayahuasca\u201d for neuropsychiatric disorders such as depression and anxiety. However, there are certain challenges when incorporating botanical ayahuasca into biomedical research and clinical therapy environments. Formulations inspired by ayahuasca, which contain specific and standardized active components, are a potential remedy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We investigated subjective acute and persisting effects of a novel formulation containing the reversible monoamine oxidase inhibitor harmine (orodispersible tablet containing 100\u2009mg MAO-I) and N,N-dimethyltryptamine (incremental intranasal dosing of up to 100\u2009mg DMT), compared with two other conditions, namely harmine alone and placebo, in a crossover RCT in 31 healthy male subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>DMT\u2009+\u2009harmine, but not harmine alone, induced a psychedelic experience assessed with the 5D-ASC rating scale [global score: <jats:italic>F<\/jats:italic>(2,60)\u2009=\u200980.21, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001] and acute experience sampling items over time, characterized by psychological insights [PIQ, <jats:italic>F<\/jats:italic>(2,58.5)\u2009=\u200928.514, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001], emotional breakthroughs [EBI, <jats:italic>F<\/jats:italic>(2,60)\u2009=\u200926.509, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001], and low scores on the challenging experience questionnaire [CEQ, <jats:italic>F<\/jats:italic>(2,60)\u2009=\u200912.84, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001]. Participants attributed personal and spiritual significance to the experience (GSR) with mainly positive persisting effects (PEQ) at 1- and 4-months follow-up. Acute drug effects correlated positively with persisting effects. We found no changes in trait measures of personality, psychological flexibility, or general well-being, and no increases in psychopathology (SCL-90-R) were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusion<\/jats:title><jats:p>Our results suggest that the experience induced by the standardized DMT\u2009+\u2009harmine formulation induces a phenomenologically rich psychedelic experience, demonstrates good psychological safety and tolerability, is well tolerated, and induces beneficial psychological processes that could possibly support psychotherapy. Further studies are required to investigate the psychotherapeutic potential in patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1302559","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T05:07:31Z","timestamp":1705036051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects"],"prefix":"10.3389","volume":"14","author":[{"given":"Helena D.","family":"Aicher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario A.","family":"Dornbierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dila","family":"Suay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudius","family":"Elsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhui","family":"Wicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Meling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzia","family":"Caflisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Hempe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Steinhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovin","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Von Rotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Kleim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Scheidegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fphar.2016.00035","article-title":"The therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization","volume":"7","author":"Frecska","year":"2016","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-3-642-40426-9_2","article-title":"The therapeutic potentials of Ayahuasca in the treatment of depression","volume-title":"The therapeutic use of Ayahuasca","author":"Palhano-Fontes","year":"2014"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.drugpo.2006.11.001","article-title":"The globalization of ayahuasca: harm reduction or benefit maximization?","volume":"19","author":"Tupper","year":"2008","journal-title":"Int J Drug Policy"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1471-0374.2009.00245.x","article-title":"Ayahuasca healing beyond the Amazon: the globalization of a traditional indigenous entheogenic practice","volume":"9","author":"Tupper","year":"2009","journal-title":"Global Netw"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/02791072.2020.1815911","article-title":"Chemical composition of traditional and analog Ayahuasca","volume":"53","author":"Kaasik","year":"2021","journal-title":"J Psychoactive Drugs"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/jat\/20.6.492","article-title":"Quantitation of N,N-dimethyltryptamine and Harmala alkaloids in human plasma after Oral dosing with Ayahuasca","volume":"20","author":"Callaway","year":"1996","journal-title":"J Anal Toxicol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s00213-022-06065-0","article-title":"Administration of NN-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT","volume":"239","author":"Barker","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","article-title":"Neuropharmacology of N,N-dimethyltryptamine","volume":"126","author":"Carbonaro","year":"2016","journal-title":"Brain Res Bull"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s002130000606","article-title":"Subjective effects and tolerability of the south American psychoactive beverage Ayahuasca in healthy volunteers","volume":"154","author":"Riba","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1124\/jpet.103.049882","article-title":"Human pharmacology of Ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics","volume":"306","author":"Riba","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1126\/science.adf0435","article-title":"Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors","volume":"379","author":"Vargas","year":"2023","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"8562","DOI":"10.1038\/s41598-022-11999-8","article-title":"Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience","volume":"12","author":"Lawrence","year":"2022","journal-title":"Sci Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231196877","article-title":"Psychological and physiological effects of extended DMT","author":"Luan","year":"2023","journal-title":"J Psychopharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","article-title":"Dose-response study of N,N-dimethyltryptamine in humans","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"16324","DOI":"10.1038\/s41598-019-51974-4","article-title":"Neural correlates of the DMT experience assessed with multivariate EEG","volume":"9","author":"Timmermann","year":"2019","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41398-023-02477-4","article-title":"Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants","volume":"13","author":"Vogt","year":"2023","journal-title":"Transl Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/02791072.2009.10399767","article-title":"Experiences of encounters with Ayahuasca\u2013\u201cthe vine of the soul\u201d","volume":"41","author":"Kjellgren","year":"2009","journal-title":"J Psychoactive Drugs"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780199252923.001.0001","volume-title":"The antipodes of the mind: Charting the phenomenology of the Ayahuasca experience","author":"Shanon","year":"2002"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/00005053-199602000-00004","article-title":"Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil","volume":"184","author":"Grob","year":"1996","journal-title":"J Nerv Ment Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/09540261.2018.1486289","article-title":"Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions","volume":"30","author":"Garcia-Romeu","year":"2018","journal-title":"Int Rev Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1055\/a-1312-7297","article-title":"Psychedelics and psychotherapy","volume":"54","author":"Nayak","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-55688-4_3","article-title":"Psychedelic medicines: a paradigm shift from pharmacological substitution towards transformation-based psychiatry","volume-title":"Ayahuasca healing and science","author":"Scheidegger","year":"2021"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/0269881120967878","article-title":"Development of the psychological insight questionnaire among a sample of people who have consumed psitlocybin or LSD","volume":"35","author":"Davis","year":"2021","journal-title":"J Psychopharmacol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J Psychopharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.36811\/jphsm.2019.110007","article-title":"Catharsis as a therapy: an overview on health and human development","author":"Bukar","year":"2019","journal-title":"J Phys Health Sports Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1037\/h0088525","article-title":"Catharsis in psychotherapy: a new perspective","volume":"22","author":"Nichols","year":"1985","journal-title":"Psychother Theory Res Pract Train"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report","volume":"37","author":"De Os\u00f3rio","year":"2015","journal-title":"Rev Bras Psiquiatr"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.brainresbull.2016.03.002","article-title":"Ayahuasca: pharmacology, neuroscience and therapeutic potential","volume":"126","author":"Dom\u00ednguez-Clav\u00e9","year":"2016","journal-title":"Brain Res Bull"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1177\/0269881116652578","article-title":"The current state of research on ayahuasca: a systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging","volume":"30","author":"Dos Santos","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"100098","DOI":"10.1016\/j.jadr.2021.100098","article-title":"Ayahuasca use and reported effects on depression and anxiety symptoms: an international cross-sectional study of 11,912 consumers","volume":"4","author":"Sarris","year":"2021","journal-title":"J Affect Disord Rep"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00213-021-06046-9","article-title":"Therapeutic effect of an ayahuasca analogue in clinically depressed patients: a longitudinal observational study","volume":"239","author":"Van Oorsouw","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3389\/fphar.2019.01325","article-title":"The impact of Ayahuasca on suicidality: results from a randomized controlled trial","volume":"10","author":"Zeifman","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","article-title":"Antidepressant effects of a single dose of Ayahuasca in patients with recurrent depression: a SPECT study","volume":"36","author":"Sanches","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration","volume":"5","author":"Kirsch","year":"2008","journal-title":"PLoS Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2018-024886","article-title":"Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis","volume":"9","author":"Munkholm","year":"2019","journal-title":"BMJ Open"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict Biol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tips.2016.01.008","article-title":"Drug tolerance: a known unknown in translational neuroscience","volume":"37","author":"Bespalov","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biol Psychiatry"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"204512532091665","DOI":"10.1177\/2045125320916657","article-title":"Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers","volume":"10","author":"Matveychuk","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.brainresbull.2016.05.016","article-title":"Ketamine abuse potential and use disorder","volume":"126","author":"Liu","year":"2016","journal-title":"Brain Res Bull"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00213-011-2434-x","article-title":"Pharmacology of ayahuasca administered in two repeated doses","volume":"219","author":"dos Santos","year":"2012","journal-title":"Psychopharmacology"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2174\/1570159X16666180125095902","article-title":"Ayahuasca: psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness","volume":"17","author":"Hamill","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/dta.1383","article-title":"Health status of ayahuasca users: health status of ayahuasca users","volume":"4","author":"Barbosa","year":"2012","journal-title":"Drug Test Anal"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugalcdep.2010.03.024","article-title":"Assessment of addiction severity among ritual users of ayahuasca","volume":"111","author":"F\u00e1bregas","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e0000438","DOI":"10.1371\/journal.pgph.0000438","article-title":"Adverse effects of ayahuasca: results from the global Ayahuasca survey","volume":"2","author":"Bouso","year":"2022","journal-title":"PLoS Glob Public Health"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1556\/2054.2019.007","article-title":"A phenomenology of subjectively relevant experiences induced by ayahuasca in upper Amazon vegetalismo tourism","volume":"3","author":"Wolff","year":"2019","journal-title":"J Psychedelic Stud"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"12307","DOI":"10.1021\/acsomega.2c00795","article-title":"New insights into the chemical composition of Ayahuasca","volume":"7","author":"Rodr\u00edguez","year":"2022","journal-title":"ACS Omega"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1556-3537.2012.01056.x","article-title":"Ayahuasca as antidepressant? Psychedelics and styles of reasoning in psychiatry","volume":"23","author":"Anderson","year":"2012","journal-title":"Anthropol Conscious"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"100410","DOI":"10.1016\/j.lana.2022.100410","article-title":"Ethical principles of traditional indigenous medicine to guide western psychedelic research and practice","volume":"18","author":"Celidwen","year":"2023","journal-title":"Lancet Reg Health"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/09687637.2013.812447","article-title":"The internationalisation of ayahuasca, edited by Beatriz C. Lebate and Henrik Jungaberle","volume":"21","author":"Aldridge","year":"2014","journal-title":"Drugs"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/archneurpsyc.1959.02340130141020","article-title":"Effect of some indolealkylamines on man","volume":"81","author":"Turner","year":"1959","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/ph13110334","article-title":"Toxicokinetics and Toxicodynamics of Ayahuasca alkaloids N,N-dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: clinical and forensic impact","volume":"13","author":"Brito-da-Costa","year":"2020","journal-title":"Pharmaceuticals"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1246892","DOI":"10.3389\/fphar.2023.1246892","article-title":"Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-dimethyltryptamine and harmine","volume":"14","author":"Dornbierer","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/02791072.2022.2079108","article-title":"Systematic review of psychometric instruments used in research with psychedelics","volume":"55","author":"de Deus Pontual","year":"2022","journal-title":"J Psychoactive Drugs"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1192\/bjp.128.3.280","article-title":"The SCL-90 and the MMPI: a step in the validation of a new self-report scale","volume":"128","author":"Derogatis","year":"1976","journal-title":"Br J Psychiatry"},{"key":"ref59","volume-title":"SCL-90-R: Symptom-Checkliste von L.R. Derogatis: Deutsche Version","author":"Franke","year":"2002"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.concog.2016.09.013","article-title":"When the dissolution of perceived body boundaries elicits happiness: the effect of selflessness induced by a body scan meditation","volume":"46","author":"Dambrun","year":"2016","journal-title":"Conscious Cogn"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"ref62","author":"Dittrich","year":"1998"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e12412","DOI":"10.1371\/journal.pone.0012412","article-title":"Psychometric evaluation of the altered states of consciousness rating scale (OAV)","volume":"5","author":"Studerus","year":"2010","journal-title":"PLoS One"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/j.drugalcdep.2014.09.118","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: demographics and phenomenology","volume":"146","author":"Carbonaro","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.beth.2011.03.007","article-title":"Preliminary psychometric properties of the acceptance and action questionnaire-II: a revised measure of psychological inflexibility and experiential avoidance","volume":"42","author":"Bond","year":"2011","journal-title":"Behav Ther"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10608-009-9276-4","article-title":"The cognitive flexibility inventory: instrument development and estimates of reliability and validity","volume":"34","author":"Dennis","year":"2010","journal-title":"Cogn Ther Res"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/0013916508318748","article-title":"The nature relatedness scale: linking individuals\u2019 connection with nature to environmental concern and behavior","volume":"41","author":"Nisbet","year":"2009","journal-title":"Environ Behav"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000376585","article-title":"The WHO-5 well-being index: a systematic review of the literature","volume":"84","author":"Topp","year":"2015","journal-title":"Psychother Psychosom"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jrp.2005.08.007","article-title":"The international personality item pool and the future of public-domain personality measures","volume":"40","author":"Goldberg","year":"2006","journal-title":"J Res Pers"},{"key":"ref72","volume-title":"R: A language and environment for statistical computing","year":"2021"},{"key":"ref73","author":"Singmann","year":"2016"},{"key":"ref74","author":"Lenth","year":"2021"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s00213-021-05817-8","article-title":"A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats","volume":"238","author":"Uthaug","year":"2021","journal-title":"Psychopharmacology"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"47","author":"Holze","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","article-title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants","volume":"48","author":"Ley","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: a review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1590\/1516-4446-2020-0913","article-title":"Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects","volume":"43","author":"Durante","year":"2021","journal-title":"Braz J Psychiatry"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1017\/S0033291715002901","article-title":"The paradoxical psychological effects of lysergic acid diethylamide (LSD)","volume":"46","author":"Carhart-Harris","year":"2016","journal-title":"Psychol Med"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/acps.12904","article-title":"Effects of psilocybin therapy on personality structure","volume":"138","author":"Erritzoe","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness","volume":"25","author":"MacLean","year":"2011","journal-title":"J Psychopharmacol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00213-017-4733-3","article-title":"Long-lasting subjective effects of LSD in normal subjects","volume":"235","author":"Schmid","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"824077","DOI":"10.3389\/fpsyg.2022.824077","article-title":"Psychedelic integration: an analysis of the concept and its practice","volume":"13","author":"Bathje","year":"2022","journal-title":"Front Psychol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J Psychopharmacol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/02791072.1997.10400190","article-title":"Set, setting, and matrix","volume":"29","author":"Eisner","year":"1997","journal-title":"J Psychoactive Drugs"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1021\/acsptsci.0c00187","article-title":"Set and setting: a randomized study of different musical genres in supporting psychedelic therapy","volume":"4","author":"Strickland","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.31234\/osf.io\/q2hzm","article-title":"Blinding and expectancy confounds in psychedelic randomised controlled trials","volume":"2021","author":"Muthukumaraswamy","year":"2021","journal-title":"PsyArXiv"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1017\/S0140525X0999152X","article-title":"The weirdest people in the world?","volume":"33","author":"Henrich","year":"2010","journal-title":"Behav Brain Sci"},{"key":"ref92","volume-title":"World mental health report","year":"2022"},{"key":"ref93","author":"Gasser","year":"2021"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1302559\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T05:07:38Z","timestamp":1705036058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1302559\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":93,"alternative-id":["10.3389\/fpsyt.2023.1302559"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1302559","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"article-number":"1302559"}}